A new
@ScienceMagazine study led by Prof. John Teijaro, PhD, found that combining ruxolitinib, an approved drug, with checkpoint inhibitors supercharged T-cell responses. This could transform
#cancer treatment, especially for tough-to-treat cancers.
More:
ow.ly/h7ol50SmP4I